HuntX Pharma

HuntX Pharma, a French biotechnology firm established in December 2022 by Laure Jamot and Frederic Saudou, is located in Grenoble, a city known for its scientific research. The company is focused on creating treatments for a range of neurological conditions that currently have no effective therapies.

The company's primary strategy is to address the underlying cause of approximately 50 different genetic neurodegenerative diseases, which they have identified as defects in axonal transport. By targeting this common mechanism, HuntX Pharma aims to develop a new class of drugs that can prevent the onset and progression of these debilitating conditions.

The initial focus of their research and development is on Huntington's disease, a fatal genetic disorder that causes the progressive breakdown of nerve cells in the brain. The company is developing oral small molecules, a type of medication that can be taken by mouth, to correct the axonal transport defects associated with this disease.

HuntX Pharma has secured $1.89 million in funding from three investors to advance its research and development programs. The company's business model is centered on the discovery and development of novel therapeutics, with the ultimate goal of bringing these treatments to market to improve the lives of patients with neurological disorders.

Keywords: neurological disorders, axonal transport, Huntington's disease, oral small molecules, genetic neurodegenerative diseases, biotechnology, therapeutics, drug development, neurosciences, pharma